Alnylam Reports Updated Interim Results from the P-I Study of ALN-APP for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Shots:
- The updated interim result from an ongoing SAD portion of the P-I study evaluating ALN-APP. The study is being conducted in two parts i.e., single ascending dose phase (part A) & multiple dose phase (part B) while the therapy is being developed in collaboration with Regeneron
- ALN-APP showed rapid & robust target engagement with sustained effect over 6mos. with a single dose & continues to show an encouraging clinical safety & tolerability profile. A single dose of ALN-APP (75mg) showed a rapid & sustained reduction in cerebrospinal fluid of sAPPα & sAPPβ, biomarkers of target engagement with reductions of 84% & 90%, respectively
- ALN-APP, an RNAi therapeutic targeting APP developed using Alnylam's C16-siRNA conjugate platform for CNS delivery
Ref: Businesswire | Image: Alnylam
Related News:- Eisai and Biogen Report the Health Canada Acceptance of New Drug Submission for Leqembi (lecanemab) to Treat Early Alzheimer's Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
